Lonza Group Ltd. Announces Additional Long-Term Agreement With Alexion
• New manufacturing line to be constructed at Lonza’s existing Portsmouth, NH (USA) plant
• Large-scale, manufacturing line will be operational by the end of 2017
• Enables Alexion to add dedicated product supply for 10 years
Basel, Switzerland, 2 July 2015 – Lonza Group Ltd today announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement.
This agreement will supplement existing production of Alexion products at multiple Lonza facilities.
The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza’s proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.
“I’m pleased to be reinforcing our long-standing strategic relationship with Alexion,” said Marc Funk, COO of Lonza. “Our new offering of suites with dedicated manufacturing capacity will give customers greater flexibility in determining production quantities and timings. At the same time, we’ll continue to offer our services in our multi-purpose plants to meet our customers’ needs.”
“Alexion is pleased to further enhance our manufacturing network with Lonza,” said Julie O’Neill, Executive Vice President, Global Operations at Alexion. “Developing a robust supply chain for our pipeline and commercial products is essential as we aim to serve more patients with our growing portfolio of life-transforming therapies.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.
Lonza Contact Information Lonza Group Ltd Head Investor Relations Dirk Oehlers Tel +41 61 316 8540 Fax +41 61 316 9540 dirk.oehlers@lonza.com
Lonza Group Ltd Head Corporate Communications Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9540 dominik.werner@lonza.com
Lonza Group Ltd Head External Communications Constance Ward Tel +41 61 316 8840 Fax +41 61 316 9840 constance.ward@lonza.com
Help employers find you! Check out all the jobs and post your resume.
• Large-scale, manufacturing line will be operational by the end of 2017
• Enables Alexion to add dedicated product supply for 10 years
Basel, Switzerland, 2 July 2015 – Lonza Group Ltd today announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement.
This agreement will supplement existing production of Alexion products at multiple Lonza facilities.
The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza’s proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.
“I’m pleased to be reinforcing our long-standing strategic relationship with Alexion,” said Marc Funk, COO of Lonza. “Our new offering of suites with dedicated manufacturing capacity will give customers greater flexibility in determining production quantities and timings. At the same time, we’ll continue to offer our services in our multi-purpose plants to meet our customers’ needs.”
“Alexion is pleased to further enhance our manufacturing network with Lonza,” said Julie O’Neill, Executive Vice President, Global Operations at Alexion. “Developing a robust supply chain for our pipeline and commercial products is essential as we aim to serve more patients with our growing portfolio of life-transforming therapies.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.
Lonza Contact Information Lonza Group Ltd Head Investor Relations Dirk Oehlers Tel +41 61 316 8540 Fax +41 61 316 9540 dirk.oehlers@lonza.com
Lonza Group Ltd Head Corporate Communications Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9540 dominik.werner@lonza.com
Lonza Group Ltd Head External Communications Constance Ward Tel +41 61 316 8840 Fax +41 61 316 9840 constance.ward@lonza.com
Help employers find you! Check out all the jobs and post your resume.